2024-07-17
On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry. The course, titled "Understand Venture Capital from the Perspective of Biotech Entrepreneur," was the opening session of the "Biopharmaceutical Investment, Financing, and Patent Protection" series under the "Hong Kong Biopharmaceutical Technology Training Program". Nearly forty participants attended this three-hour training event. As a seasoned investor in the life science sector, Mr. Yang shared insights on topics related to biopharmaceuticals and venture capital, engaging in interactive discussions with the participants and providing valuable references and inspiration.
The "Hong Kong Biopharmaceutical Technology Training Program" is organized by the HK Bio-Med Innotech Association and executed by the Hong Kong Productivity Council. It aims to enhance the diversity and quality of talent in Hong Kong's biopharmaceutical industry and increase the industry's competitiveness. The series will cover topics such as biopharmaceutical commercialization and development, drug research company investment and financing, patent protection, and technology transfer in drug research and production.
Mr. Yang reviewed the global biopharmaceutical venture capital and secondary market trends over the past decade, with a particular focus on the primary market investment trends, secondary market performance, and current opportunities and challenges in the healthcare sectors of the United States, Europe, and China.
As the core of the course, Mr. Yang explained how venture capital operates, including the selection of investment targets and the decision-making mechanisms of venture capital. Using Sequoia Capital and Novo Holdings as examples, he analyzed different investment styles, organized participant discussions, and shared the development history of the leading biotech company Amgen. Mr. Yang introduced transaction terms and valuation methods related to venture capital and offered advice on writing an effective business plan. He also emphasized how to seize opportunities in the current environment of Hong Kong's innovation and technology development, leveraging government and venture capital resources to promote the growth of life science startups.
The lecture was held successfully, with enthusiastic discussions and positive feedback from the participants. As a venture capital firm focused on the life sciences sector, Blue Ocean Capital Group will continue to advance innovation and development in the life sciences industry in the Greater Bay Area and globally, and keep moving forward with entrepreneurs, scientists, and business leaders.
